Stockreport

Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

Axsome Therapeutics, Inc.  (AXSM) 
Last axsome therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: axsome.com
PDF FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. [Read more]